Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 3/20 | 0.34 |
| ▸ | FNTB | P49356 | 3/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 8/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205333 | 0.89 | MEN1 (0.49) | MEN1KMT2ARXFP1HPGDMAPK1 | |
| SCHEMBL5722642 | 0.84 | MEN1 (0.52) | MEN1KMT2ARXFP1HPGDMAPK1 | |
| SCHEMBL5657976 | 0.81 | MEN1 (0.51) | MEN1KMT2ARXFP1HPGDMAPK1 | |
| SCHEMBL4289870 | 0.79 | HSD17B10 (0.39) | FNTAFNTBHSD17B1 | |
| SCHEMBL5657749 | 0.77 | MEN1 (0.52) | MEN1KMT2ARXFP1HPGDMAPK1 | |
| SCHEMBL5550240 | 0.74 | MEN1 (0.49) | MEN1KMT2ARXFP1HPGDHTT | |
| SCHEMBL1538310 | 0.73 | MEN1 (0.59) | MEN1KMT2ARXFP1HPGDMAPK1 | |
| SCHEMBL5023770 | 0.72 | KDM4E (0.52) | MEN1KMT2AHPGDMAPK1PDE4A | |
| SCHEMBL5780432 | 0.70 | RXFP1 (0.52) | MEN1KMT2ARXFP1MAPK1HTT | |
| SCHEMBL11947173 | 0.69 | MEN1 (0.60) | MEN1KMT2ARXFP1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | MEN1 1584/4885KMT2A 1530/4885RXFP1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.